All Stories

  1. Faecal microbiota transplantation: A sui generis biological drug, not a tissue

    Article • Annales Pharmaceutiques Françaises, July 2014, Elsevier

    Ruth Lopert

  2. Reply by authors

    Article • Health Policy, June 2014, Elsevier

    Ruth Lopert, Deborah Gleeson

  3. Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries

    Article • The European Journal of Health Economics, May 2014, Springer Science + Business Media

    Ruth Lopert

  4. Biosimilars And The European Experience: Implications For The United States

    Article • Health Affairs, October 2013, Health Affairs

    Ruth Lopert

  5. Applying rapid ‘de-facto’ HTA in resource-limited settings: Experience from Romania

    Article • Health Policy, October 2013, Elsevier

    Ruth Lopert

  6. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand

    Article • Health Policy, October 2013, Elsevier

    Ruth Lopert, Deborah Gleeson

  7. Intussusception Risk and Disease Prevention Associated With Rotavirus Vaccines in Australia's National Immunization Program

    Article • Clinical Infectious Diseases, August 2013, Oxford University Press (OUP)

    Ruth Lopert

  8. Australia's 'Fourth Hurdle' Drug Review Comparing Costs And Benefits Holds Lessons For The United States

    Article • Health Affairs, April 2013, Health Affairs

    Ruth Lopert

  9. Willingness To Pay For Cancer Therapy

    Article • Health Affairs, August 2012, Health Affairs

    Ruth Lopert

  10. Simulated Value-Based Insurance Design Applied to Statin Use by Medicare Beneficiaries with Diabetes

    Article • Value in Health, May 2012, Elsevier

    Ruth Lopert

  11. Does Medication Adherence Lower Medicare Spending among Beneficiaries with Diabetes?

    Article • Health Services Research, March 2011, Wiley

    Ruth Lopert

  12. PCV98 IMPACT OF MEDICATION ADHERENCE ON HEALTH CARE EXPENDITURES BY MEDICARE BENEFICIARIES WITH HEART FAILURE

    Article • Value in Health, November 2010, Elsevier

    Ruth Lopert

  13. Panvax febrile reactions not a predictor

    Article • BMJ, July 2010, BMJ

    Ruth Lopert

  14. Comparative Effectiveness Research and Evidence‐Based Health Policy: Experience from Four Countries

    Article • Milbank Quarterly, June 2009, Wiley

    Ruth Lopert

  15. CASE2 TOWARDS AN INTEGRATED APPROACH TO THE ASSESSMENT OF SURROGATE OUTCOME DATA

    Article • Value in Health, May 2009, Elsevier

    Ruth Lopert

  16. PBS copayments and safety nets - A commentary on Sweeny and Doran and Robertson

    Article • Australian Health Review, January 2009, CSIRO Publishing

    Ruth Lopert

  17. Prices for Innovative Pharmaceutical Products That Provide Health Gain: A Comparison Between Australia and the United States

    Article • Value in Health, November 2007, Elsevier

    Ruth Lopert

  18. International Price Comparisons for Novel and Follow-on Drugs: A Response

    Article • Value in Health, November 2007, Elsevier

    Ruth Lopert

  19. Toward A Rational, Value-Based Drug Benefit For Medicare

    Article • Health Affairs, November 2007, Health Affairs

    Ruth Lopert

  20. What is Fair? Choice, Fairness, and Transparency in Access to Prescription Medicines in the United States and Australia

    Article • The Journal of Law Medicine & Ethics, January 2007, Cambridge University Press

    Ruth Lopert

  21. Use of pharmacoeconomics in prescribing research. Part 5: modelling - beyond clinical trials

    Article • Journal of Clinical Pharmacy and Therapeutics, October 2003, Hindawi Publishing Corporation

    Ruth Lopert

  22. Use of pharmacoeconomics in prescribing research. Part 3: cost-effectiveness analysis - a technique for decision-making at the margin

    Article • Journal of Clinical Pharmacy and Therapeutics, June 2003, Hindawi Publishing Corporation

    Ruth Lopert

  23. Differential pricing of drugs: a role for cost-effectiveness analysis?

    Article • The Lancet, June 2002, Elsevier

    Ruth Lopert

  24. PMDH3: THE USE OF SURROGATE ENDPOINT DATA IN EVALUATING TREATMENT EFFICACY: IMPACT ON DECISION-MAKING AND EXPENDITURE WITHIN THE AUSTRALIAN PHARMACEUTICAL BENEFITS SCHEME

    Article • Value in Health, September 2000, Elsevier

    Ruth Lopert

  25. Pharmacoeconomics and policy decisions: The australian health care system

    Article • Clinical Therapeutics, May 1999, Elsevier

    Ruth Lopert

  26. A Randomized Controlled Trial of Piroxicam in the Management of Acute Ankle Sprain in Australian Regular Army Recruits

    Article • The American Journal of Sports Medicine, July 1997, SAGE Publications

    Ruth Lopert

  27. Drug-Induced Delirium

    Article • Drug Safety, October 1996, Springer Science + Business Media

    Ruth Lopert